Navigation Links
Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Date:8/11/2014

LA JOLLA, Calif., Aug. 11, 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, today announced it has signed an agreement with Celgene Cellular Therapeutics (CCT) to license, develop, and co-promote Celgene's proprietary placental cell population, PSC-100.

HLI has the option to explore a variety of applications for this unique cell population, including for sarcopenia, a condition associated with aging characterized by degenerative loss of skeletal muscle mass, quality, and strength. Celgene has also made an equity investment in HLI.

HLI will use its vast expertise and technology to sequence and characterize PSC-100 at the molecular level to complement data Celgene has gleaned from PSC-100 in Phase 1 human studies.

"We think that cellular based therapeutics combined with our genomics based discovery systems offer exciting potential for age-related diseases," said J. Craig Venter, Ph.D., HLI CEO and Co-Founder.  "PSC-100 provides an advanced basis of testing cell therapy for diseases like sarcopenia," he concluded.

HLI's primary business is focused on building the world's most comprehensive human genotype and phenotype database to tackle the diseases associated with aging-related human biological decline. Given that stem cells are an important component to understanding and unlocking many insights into human biology and human disease, the company is also exploring development of cell-based therapeutics to address age-related decline in endogenous stem cell function.

HLI's work is premised on the theory that as the human body ages many biological changes occur, including substantial changes and degradation to the genome of the differentiated, specialized cells found in all body tissues. There is also a depletion and degradation of healthy regenerative stem cell populations in the body over time. In addition to its own work in stem cells the agreement with CCT offers HLI another immediate and important avenue for research and development in stem cells and cellular therapeutics.

HLI's Co-Founder, Robert Hariri, M.D., Ph.D., who is also Chairman, Founder, Chief Scientific Officer and former Chief Executive Officer of CCT, is a pioneer in the use of stem cells to treat a variety of life threatening diseases. Dr. Hariri and his team were the first to discover and characterize pluripotent stem cells from the placenta and also developed PSC-100.

About Human Longevity, Inc.
HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit, www.humanlongevity.com

Logo - http://photos.prnewswire.com/prnh/20140304/LA76169LOGO


'/>"/>
SOURCE Human Longevity, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. Nearby chimpanzee populations show much greater genetic diversity than distant human populations
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
4. A birds song may teach us about human speech disorders
5. Scientists produce eye structures from human blood-derived stem cells
6. Human noise has ripple effects on plants
7. Did climate change shape human evolution?
8. Harmless human virus may be able to boost the effects of chemotherapy
9. Study resolves debate on human cell shut-down process
10. Fine-scale analysis of the human brain yields insight into its distinctive composition
11. Bartonella infection associated with rheumatoid illnesses in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received ... innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned ... syringe. The company’s solutions are the first Wharton’s jelly allograft product to be recognized ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has ... Invictus Medical Neoasis™ active noise control device to attenuate typical noises in a ... device attenuated the alarm sounds from patient monitors, ventilators and other bedside devices ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... FRANCISCO (PRWEB) , ... July ... ... provider of cloud-based software for the life sciences industry, today announced the ... presentation platform designed specifically for Medical Science Liaisons (MSLs) and other field ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said ... on the market and we were pleased that the IFT jury recognized that.” reFRESH™ ... creating a natural way to extend the shelf life and improve the safety of ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... products, announces a significant expansion of laboratory operations through its COVID-19 testing ... implementing testing programs. , Bode-CARES provides a turnkey solution that ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
Breaking Biology Technology: